Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on January 10, 2019. The registrant is a Delaware corporation headquartered in Boulder, CO, and is classified as an emerging growth company. The filing reports on "Other Events" related to clinical trial data announcements.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the issuance of a press release on January 10, 2019, announcing:
- Data from a Phase 1 clinical trial evaluating cobomarsen (a microRNA-155 inhibitor) in patients with cutaneous T-cell lymphoma (CTCL) and adult T-cell lymphoma/leukemia (ATLL).
- Initial data from a Phase 1 clinical trial of cobomarsen in patients with diffuse large B-cell lymphoma (DLBCL).
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) by reference but does not provide specific management commentary, financial guidance, or risk factors within the text of the 8-K itself. The primary focus is the disclosure of clinical trial progress.
Investor Verification Checklist
- Verify the specific clinical data results in the attached Exhibit 99.1 (Press Release), as the 8-K text only summarizes the announcement.
- Confirm the company name is Miragen Therapeutics, Inc. (the input metadata listed Viridian Therapeutics, Inc., which appears to be an error).
- Review the company's most recent 10-K or 10-Q for financial health metrics, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on the Phase 1 trials for CTCL, ATLL, and DLBCL.